Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC, discusses how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
This on-demand webinar was originally broadcast on April 30, 2026.
What should you expect to learn from this webinar?
• Understand the clinical use cases for fast, front-line NGS testing in oncology.
• Learn how MSKCC validated and implemented the oncoReveal Nexus 21-gene Panel (MSK-REACT).
• Review the performance of this targeted, rapid panel alongside CGP (MSK-IMPACT).
• Discover how NGS turnaround times are optimized utilizing the Illumina MiSeq i100
and Hamilton STARlet.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.